Skip to main content
Erschienen in: Journal of Neurology 4/2011

01.04.2011 | Original Communication

Gait variability in Parkinson’s disease: an indicator of non-dopaminergic contributors to gait dysfunction?

verfasst von: Sue Lord, Katherine Baker, Alice Nieuwboer, David Burn, Lynn Rochester

Erschienen in: Journal of Neurology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Gait variability has potential utility as a predictive measure of dysfunction in Parkinson’s disease (PD). Current understanding implicates non-dopaminergic pathways. This study investigated the explanatory characteristics of gait variability in PD on and off medication under single and dual task conditions. Fifty people with PD were assessed twice at home (on and off l-dopa) whilst walking under single and dual task conditions, and variability (coefficient of variation, CV) was calculated for stride time and double limb support (DLS) time. Hierarchical regression analysis was used to identify predictors. The first block of variables included age, gait speed, depression (Hospital Anxiety and Depression Scale) and fatigue (Multidimensional Fatigue Inventory), and the second block included motor severity (UPDRS III), executive function (Hayling and Brixton) and attention (Test of Everyday Attention). Motor severity predicted stride time variability and DLS time variability independent of l-dopa during single task gait. Dual task gait yielded a more complex picture. Depression made a unique contribution of 9.0% on medication and 5.0% off medication to stride time variability, and visual attention and younger age contributed to DLS variability on medication, explaining 3% and 2%, respectively. Motor severity predicted DLS variability off medication, explaining 74% of variance. Different characteristics explain the two measures of gait variability, pointing to different control mechanisms.
Literatur
1.
Zurück zum Zitat Blin O, Ferrandez AM, Pailhous J, Serratrice G (1991) Dopa-sensitive and dopa-resistant gait parameters in Parkinson’s disease. J Neurol Sci 103:51–54PubMedCrossRef Blin O, Ferrandez AM, Pailhous J, Serratrice G (1991) Dopa-sensitive and dopa-resistant gait parameters in Parkinson’s disease. J Neurol Sci 103:51–54PubMedCrossRef
2.
Zurück zum Zitat O’Sullivan J, Said C, Dillon L, Hoffman M, Hughes A (1998) Gait analysis in patients with Parkinson’s disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov Disord 13:900–906PubMedCrossRef O’Sullivan J, Said C, Dillon L, Hoffman M, Hughes A (1998) Gait analysis in patients with Parkinson’s disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov Disord 13:900–906PubMedCrossRef
3.
Zurück zum Zitat Gabell A, Nayak U (1984) The effect of age on variability in gait. J Gerontol 39(6):662–666PubMed Gabell A, Nayak U (1984) The effect of age on variability in gait. J Gerontol 39(6):662–666PubMed
4.
Zurück zum Zitat Hausdorff JM (2007) Gait dynamics, fractals and falls: finding meaning in the stride-to-stride fluctuations of human walking. Hum Mov Sci 26:557–589CrossRef Hausdorff JM (2007) Gait dynamics, fractals and falls: finding meaning in the stride-to-stride fluctuations of human walking. Hum Mov Sci 26:557–589CrossRef
5.
Zurück zum Zitat Springer S, Giladi N, Peretz C, Yogev G, Simon ES, Hausdorff JM (2006) Dual-tasking effects on gait variability: the role of aging falls and executive function. Mov Disord 7:950–957CrossRef Springer S, Giladi N, Peretz C, Yogev G, Simon ES, Hausdorff JM (2006) Dual-tasking effects on gait variability: the role of aging falls and executive function. Mov Disord 7:950–957CrossRef
6.
Zurück zum Zitat Camicioli R, Wieler M, de Frias C, Martin W (2008) Early, untreated Parkinson’s disease patients show reaction time variability. Neurosci Lett 441:77–80PubMedCrossRef Camicioli R, Wieler M, de Frias C, Martin W (2008) Early, untreated Parkinson’s disease patients show reaction time variability. Neurosci Lett 441:77–80PubMedCrossRef
7.
Zurück zum Zitat Almeida QJ, Wishart LR, Lee TD (2002) Bimanual co-ordination deficits with Parkinson’s disease: the influence of movement speed and external cueing. Mov Disord 17(1):30–37PubMedCrossRef Almeida QJ, Wishart LR, Lee TD (2002) Bimanual co-ordination deficits with Parkinson’s disease: the influence of movement speed and external cueing. Mov Disord 17(1):30–37PubMedCrossRef
8.
Zurück zum Zitat Baltadjieva R, Giladi N, Gruendinger L, Peretz C, Hausdorff JM (2006) Marked alterations in the gait timing and rhythmicity of patients with de novo Parkinson’s disease. Eur J Neurosci 24:1815–1820PubMedCrossRef Baltadjieva R, Giladi N, Gruendinger L, Peretz C, Hausdorff JM (2006) Marked alterations in the gait timing and rhythmicity of patients with de novo Parkinson’s disease. Eur J Neurosci 24:1815–1820PubMedCrossRef
9.
Zurück zum Zitat Grimbergen YAM, Langston JW, Roos RAC, Bloem BR (2009) Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 92:279–290CrossRef Grimbergen YAM, Langston JW, Roos RAC, Bloem BR (2009) Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 92:279–290CrossRef
10.
Zurück zum Zitat Lord S, Rochester L, Hetherington V, Allock LM, Burn D (2010) Executive function and attention contribute to gait interference in ‘off’ state Parkinson’s disease. Gait Posture 31(2):169–174PubMedCrossRef Lord S, Rochester L, Hetherington V, Allock LM, Burn D (2010) Executive function and attention contribute to gait interference in ‘off’ state Parkinson’s disease. Gait Posture 31(2):169–174PubMedCrossRef
11.
Zurück zum Zitat Rochester L, Nieuwboer A, Baker K, Hetherington V, Willems A-M, Kwakkel G et al (2008) Walking speed during single and dual tasks in Parkinson’s disease: which characteristics are important? Mov Disord 23(16):2312–2318PubMedCrossRef Rochester L, Nieuwboer A, Baker K, Hetherington V, Willems A-M, Kwakkel G et al (2008) Walking speed during single and dual tasks in Parkinson’s disease: which characteristics are important? Mov Disord 23(16):2312–2318PubMedCrossRef
12.
Zurück zum Zitat Rochester L, Hetherington V, Jones D, Nieuwboer A, Willems A, Kwakkel G et al (2004) Attending to the task: interference effects of functional tasks on walking in Parkinson’s disease and the roles of cognition, depression, fatigue and balance. Arch Phys Med Rehabil 85:1578–1585PubMedCrossRef Rochester L, Hetherington V, Jones D, Nieuwboer A, Willems A, Kwakkel G et al (2004) Attending to the task: interference effects of functional tasks on walking in Parkinson’s disease and the roles of cognition, depression, fatigue and balance. Arch Phys Med Rehabil 85:1578–1585PubMedCrossRef
13.
Zurück zum Zitat Hoehn MH, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 5:427–442 Hoehn MH, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 5:427–442
14.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198PubMedCrossRef Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198PubMedCrossRef
15.
Zurück zum Zitat Goetz CG, Stebbins GT, Shale HM (1994) Utility of an objective dyskinesia rating scale for grading the cognitive state of patients for the clinician. Mov Disord 9:390–394PubMedCrossRef Goetz CG, Stebbins GT, Shale HM (1994) Utility of an objective dyskinesia rating scale for grading the cognitive state of patients for the clinician. Mov Disord 9:390–394PubMedCrossRef
16.
Zurück zum Zitat Krause M, Fogel W, Heck W, Hacke W, Bonsanto M, Trenkwalder C (2001) Deep brain stimulation for the treatment of Parkinson’s disease: subthalamic nucleus versus globus pallidus internus. J Neurol Neurosurg Psychiatry 70:464–470PubMedCrossRef Krause M, Fogel W, Heck W, Hacke W, Bonsanto M, Trenkwalder C (2001) Deep brain stimulation for the treatment of Parkinson’s disease: subthalamic nucleus versus globus pallidus internus. J Neurol Neurosurg Psychiatry 70:464–470PubMedCrossRef
17.
Zurück zum Zitat Fahn S, Elton RL (1987) Members of the UPDRS development committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. MacMillan Healthcare Information, Florham Park, pp 153–163 Fahn S, Elton RL (1987) Members of the UPDRS development committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. MacMillan Healthcare Information, Florham Park, pp 153–163
18.
Zurück zum Zitat Nieuwboer A, Rochester L, Herman T, Vandeberghe W, Ehab Emil G, Thomaes T et al (2009) The new freezing of gait questionnaire: ratings from patients with Parkinson’s disease and their carers. Gait Posture 30(4):459–463PubMedCrossRef Nieuwboer A, Rochester L, Herman T, Vandeberghe W, Ehab Emil G, Thomaes T et al (2009) The new freezing of gait questionnaire: ratings from patients with Parkinson’s disease and their carers. Gait Posture 30(4):459–463PubMedCrossRef
19.
Zurück zum Zitat Burgess P, Shallice T (1997) The Hayling and Brixton tests. Thames Valley Test Company Ltd, Bury St Edmonds Burgess P, Shallice T (1997) The Hayling and Brixton tests. Thames Valley Test Company Ltd, Bury St Edmonds
20.
Zurück zum Zitat Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I (1994) The test of everyday attention: Bury St. Thames Valley Test Company, Edmonds Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I (1994) The test of everyday attention: Bury St. Thames Valley Test Company, Edmonds
21.
Zurück zum Zitat Smets EM, Garseen B, Bonke B, De Haes JC (1995) The multidimensional fatigue inventory (MFI) psychometric properties of an instrument to assess fatigue. J Psychosom Res 19(39):315–325CrossRef Smets EM, Garseen B, Bonke B, De Haes JC (1995) The multidimensional fatigue inventory (MFI) psychometric properties of an instrument to assess fatigue. J Psychosom Res 19(39):315–325CrossRef
22.
Zurück zum Zitat Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef
23.
Zurück zum Zitat Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM (2003) Gait dynamics in Parkinson’s disease: relationship to Parkinsonism features, falls and response to levodopa. J Neurol Sci 212:47–53PubMedCrossRef Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM (2003) Gait dynamics in Parkinson’s disease: relationship to Parkinsonism features, falls and response to levodopa. J Neurol Sci 212:47–53PubMedCrossRef
24.
Zurück zum Zitat Morris M, McGinley J, Huxham F, Collier J, Iansek R (1999) Constraints on the kinetic, kinematic and spatiotemporal parameters of gait in Parkinson’s disease. Hum Mov Sci 18:461–483CrossRef Morris M, McGinley J, Huxham F, Collier J, Iansek R (1999) Constraints on the kinetic, kinematic and spatiotemporal parameters of gait in Parkinson’s disease. Hum Mov Sci 18:461–483CrossRef
26.
Zurück zum Zitat Rommelfanger D, Weinshenker D (2007) Norepineprhine: the redheaded stepchild of Parkinson’s disease. Biochem Pharmacol 74:177–190PubMedCrossRef Rommelfanger D, Weinshenker D (2007) Norepineprhine: the redheaded stepchild of Parkinson’s disease. Biochem Pharmacol 74:177–190PubMedCrossRef
27.
Zurück zum Zitat Lemke M (2008) Depressive symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 1):21–25PubMedCrossRef Lemke M (2008) Depressive symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 1):21–25PubMedCrossRef
28.
Zurück zum Zitat Haumaue N, Ogat A, Terado M, Ohno K, Kikuchi S, Sasaki H (2006) Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus. Neurochem Res 31:1451–1455CrossRef Haumaue N, Ogat A, Terado M, Ohno K, Kikuchi S, Sasaki H (2006) Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus. Neurochem Res 31:1451–1455CrossRef
29.
Zurück zum Zitat Cools R, Barker RA, Sahakian BJ, Robins TW (2001) Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands. Cereb Cortex 11:1136–1143PubMedCrossRef Cools R, Barker RA, Sahakian BJ, Robins TW (2001) Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands. Cereb Cortex 11:1136–1143PubMedCrossRef
Metadaten
Titel
Gait variability in Parkinson’s disease: an indicator of non-dopaminergic contributors to gait dysfunction?
verfasst von
Sue Lord
Katherine Baker
Alice Nieuwboer
David Burn
Lynn Rochester
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 4/2011
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-010-5789-8

Weitere Artikel der Ausgabe 4/2011

Journal of Neurology 4/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.